人类白细胞抗原
肺癌
生物标志物
免疫疗法
癌症
免疫学
抗原
医学
生物
免疫系统
肿瘤科
遗传学
内科学
标识
DOI:10.1158/1078-0432.ccr-23-2152
摘要
Abstract HLA evolutionary divergence reflects the ability to recognize diverse neoantigens as non-self, and as a biomarker is conceptually distinct from programmed cell death ligand 1 expression and tumor mutation burden. HLA based assays to predict benefit from immunotherapy in lung cancer require prospective validation.
科研通智能强力驱动
Strongly Powered by AbleSci AI